FDA greenlights Boehringer’s COPD treatment
Ingelheim/Ridgefield –Boehringer Ingelheim’s COPD treatment Combivent Respimat has been approved by the U.S. Food and Drug Administration (FDA) for the US market. The new, propellant-free inhaler product for the beta adrenergic agonist albuterol sulfate will be available for patients in mid-2012, Boehringer’s US arm announced yesterday. Combivent Respimat, which will replace Boehringer Ingelheim’s Combivent MDI by the end of 2013, targets the same patient group that requires a second bronchodilator due to occurrence of bronchospasms after use of a regular aerosol bronchodilator. Chronic obstructive pulmonary disease (COPD) makes it harder to breathe because less air is able to flow in and out of the lungs. The disease affects 24 million Americans and is the fourth leading cause of death in the United States. It kills more people each year than breast cancer and diabetes combined.